Novo Nordisk And Gilead Expand NASH Alliance
Duo Exploring Combo Approaches To Treat Cirrhosis
Executive Summary
Novo Nordisk and Gilead Sciences have expanded their clinical collaboration in non-alcoholic steatohepatitis following positive data from a proof-of-concept trial.
You may also be interested in...
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
CohBar’s First Mitochondria Based Therapy Shows Promise In NASH
The first clinical results from its mitochondrial derived peptide pipeline is good news for CohBar, but it needs investors or big pharma partners to help it progress.
Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.